Understanding how TRIM56 helps fight HIV-1
Antiretroviral mechanisms of TRIM56
This study is looking at how a protein called TRIM56 helps fight the HIV virus, which causes AIDS, and aims to find new ways to improve treatments for people living with HIV.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11084884 on NIH RePORTER |
What this research studies
This research investigates the role of TRIM56, an innate immune effector, in restricting HIV-1, the virus that causes AIDS. The project aims to uncover the molecular mechanisms by which TRIM56 exerts its antiviral effects, focusing on its unique ability to interact with viral RNA. By exploring how TRIM56 binds to HIV-1 and affects viral stability and packaging, the research seeks to identify new therapeutic targets for HIV treatment. Patients may benefit from insights gained that could lead to more effective anti-HIV therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who are seeking new treatment options.
Not a fit: Patients who are not infected with HIV-1 or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating HIV-1, potentially improving outcomes for patients living with HIV/AIDS.
How similar studies have performed: Previous research has shown promise in understanding the antiviral mechanisms of innate immune effectors, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Parsons, Molly Frances — Boston Children's Hospital
- Study coordinator: Parsons, Molly Frances
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.